No one said “sell everything.” All i'm saying: don’t price in $1.50 like it’s guaranteed when Q2 performance doesn’t even exist yet.
Dismissing downside as a “third standard deviation” while celebrating $1.50 targets as inevitable isn’t investing — it’s narrative cherry-picking. You can’t mock risk management 101 and then pretend your upside case is bulletproof.
Plenty of biotechs hit “peak pessimism” and stayed there… permanently.
If you truly believed 25,000 subs by June 30 was a 3-sigma event, you'd be betting your house. But you’re not — because deep down, you know there’s a gap between hype and results, and we’re still in that gap.
BOT Price at posting:
30.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)